• Return to Headlines

Shares of Allergan Plc Rank the Highest in Terms of EBITDA Growth in the Pharmaceuticals Industry (AGN, ANIP, LLY, SUPN, MRK)

By Nick Russo

Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Allergan Plc ranks highest with a EBITDA growth of 354.9%. Following is Ani Pharmaceutic with a EBITDA growth of 90.3%. Eli Lilly & Co ranks third highest with a EBITDA growth of 60.9%.

Supernus Pharmac follows with a EBITDA growth of 59.4%, and Merck & Co rounds out the top five with a EBITDA growth of 58.9%.

SmarTrend recommended that subscribers consider buying shares of Eli Lilly & Co on May 11th, 2018 as our technology indicated a new Uptrend was in progress when shares hit $81.74. Since that recommendation, shares of Eli Lilly & Co have risen 25.1%. We continue to monitor Eli Lilly & Co for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest ebitda growth allergan plc ani pharmaceutic eli lilly & co supernus pharmac Merck & Co

Ticker(s): AGN ANIP LLY SUPN MRK